Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 237Recurrence 24Neoplasms, Plasma Cell 22Immunoglobulin Light-chain Amyloidosis 18Amyloidosis 10Smoldering Multiple Myeloma 8Lymphoma, Non-Hodgkin 5Lymphoma 5Lymphoma, T-Cell, Cutaneous 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Plasma Cell 4Hodgkin Disease 4Sezary Syndrome 3Renal Insufficiency 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Plasmacytoma 3Neoplasms 3Nausea 3Mycosis Fungoides 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Hematologic Neoplasms 3Burkitt Lymphoma 3Blast Crisis 3Vomiting 2Testicular Neoplasms 2

Interventions

dacetuzumab 2Bortezomib 2Vorinostat 1Tinzaparin 1Lenalidomide 1Dexamethasone 1Calcium Dobesilate 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemostatic Disorders × Calcium Dobesilate × Plasma cell × Clear all
NCT00525447 2014-10-09

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

Seagen Inc.

Phase 1 Completed
36 enrolled
LymphoidPlasma cell

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡